Search clinical trials for: Mavrilimumab

Total 12 results

MedImmune Ltd

Completed

A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Germany
MedImmune LLC
MedImmune Ltd

Completed

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Poland, Russian Federation, South Africa, Spain, Estonia, Hungary, Ukraine, Argentina, Chile, Germany, Serbia, Czech Republic, Colombia
MedImmune LLC
MedImmune Ltd

Completed

A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Poland, Russian Federation, Estonia, Hungary, Latvia, Lithuania, Romania, Ukraine, Czechia, Japan
MedImmune LLC

Terminated

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Poland, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Hungary, Ukraine, Argentina, Chile, Czechia, Israel, Slovakia, Greece, Germany, Serbia, Colombia, Mexico
MedImmune LLC

Completed

A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

Healthy Volunteers

United Kingdom
Kiniksa Pharmaceuticals, Ltd.

Completed

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

COVID

United States, Brazil, South Africa, Chile, Peru
Virginia Commonwealth University
Kiniksa Pharmaceuticals, Ltd.

Completed

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

COVID-19 | Pneumonia | Sars-CoV2

United States
The Cleveland Clinic
Kiniksa Pharmaceuticals, Ltd.

Completed

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Pneumonia | SARS-CoV 2 | COVID 19

United States
Ospedale San Raffaele

Unknown

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) (COMBAT-19)

Covid-19 | Acute Respiratory Failure | ARDS, Human | Sars-CoV2 | Viral Pneumonia

Italy
Kristin Hudock
Kiniksa Pharmaceuticals, Ltd.

Unknown

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation

Pneumonia | SARS-CoV 2 | COVID 19

United States
MedImmune LLC

Completed

A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation, Spain, United Kingdom, Argentina, Hungary, Israel, Portugal, Slovakia, Greece, Serbia, Czech Republic, Colombia, France, Mexico
Kiniksa Pharmaceuticals, Ltd.

Completed

KPL-301 for Subjects With Giant Cell Arteritis

Giant Cell Arteritis

United States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain

Search clinical trials for: Mavrilimumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations